Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond, a first in the healthcare industry.

Sep 16, 2020
Patient and healthcare worker in Vietnam

Novartis reinforces its commitment to environmental, social and governance (ESG) principles and the recently announced 2025 Patient Access Targets, pricing a EUR 1.85 billion sustainability-linked bond (SLB).

The new bond is the first of its kind in the healthcare industry and the first SLB incorporating social targets. The SLB represents another step in the company’s journey to further embed ESG into the core of its business operations and to communicate progress in a consistent and transparent way.

Learn More

Ambitious ESG targets

Woman receiving medicine at dispensary in Kenya

 

Novartis recently set new ambitious targets to increase patient reach in low- and middle-income countries by 2025. In addition, Novartis further strengthened its carbon neutrality target to aim for full carbon neutrality across its supply chain (Scope 1, 2, 3) by 2030. Read More 

Novartis US Foundation to help improve health equity

People in a busy city in the US

 

The Novartis US Foundation announced a total commitment of USD 25 million to develop partnerships and fund community organizations and programs that address health inequities, with a focus on diversity in clinical trials, in the United States. This commitment reinforces the foundation’s mission to improve health in underserved communities in the United States by creating innovative and sustainable solutions to expand access to healthcare and build trust within the healthcare system. Read More

Our approach to Environmental, Social and Governance topics

Novartis aims to hold itself to the highest standards of sustainability and ethical business practices. We take bold steps to increase access to medicines, tackle complex global health challenges, and do our part as a responsible corporate citizen.

Learn More